Blue Water Vaccines, developing universal flu vaccine, closes $7 million led by CincyTech

(CincyTech) Blue Water Vaccines, a company developing a universal flu vaccine based on technology developed at the University of Oxford, has closed a $7 million seed capital round led by CincyTech. The round was oversubscribed, with additional participation from CincyTech-affiliated private investors. The financing follows a successful preclinical study which offered early validation of the company's novel approach to vaccine design.